{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:20:38Z","timestamp":1793229638815,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hemophilia A and B are X-linked coagulation disorders characterized by low or dysfunctional Factor VIII (FVIII) or IX (FIX), respectively. Currently, hemophilia A and B are treated by FVIII\/FIX replacement therapy with plasma-derived or recombinant products or by FVIII-mimetic agents (e.g., emicizumab). More recently, gene therapy (GT) has been developed and licensed for use in patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Content<\/jats:title>\n                  <jats:p>In recent years, adeno-associated viral vectors (AAVV) have been developed as a means to transfer genetic material into liver cells. Clinical trials of patients with hemophilia A or B have shown that GT is effective at sustaining plasma levels of FVIII\/FIX and reducing bleeding. Important issues must be considered with GT, including the gene, the delivery method, the target organ, and the measurement of the FVIII\/IX produced thereafter.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Several conclusions can be drawn about GT in hemophilia A and B based on the literature and clinical practice. First, relevant gene material (FVIII\/FIX) can be incorporated into AAVV, which is then infused into patients. AAVV targets liver cells and produces FVIII\/IX. Second, the selection of patients who should be free from liver disease is paramount for successful therapy. Third transgene factors can be measured by one-stage clotting (OSA) or chromogenic assays (CA). Based on results from clinical trials, OSA measures transgene factor levels that are approximately 2 times higher than CA. Although expert opinions favor the OSA for transgene FIX and CA for transgene FVIII, no firm evidence is yet available on which method is better associated with clinical outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvaf085","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T19:50:11Z","timestamp":1755028211000},"page":"1024-1035","source":"Crossref","is-referenced-by-count":6,"title":["Gene Therapy for Hemophilias: Opportunities and Challenges for the Clinical Laboratory"],"prefix":"10.1093","volume":"71","author":[{"given":"Armando","family":"Tripodi","sequence":"first","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center , Milano ,","place":["Italy"]},{"name":"Fondazione Luigi Villa , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Garagiola","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center , Milano ,","place":["Italy"]},{"name":"Fondazione Luigi Villa , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Bitto","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"La Mura","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center , Milano ,","place":["Italy"]},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center , Milano ,","place":["Italy"]},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"2025100219514318800_hvaf085-B1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"2025100219514318800_hvaf085-B2","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"2025100219514318800_hvaf085-B3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/hae.13816","article-title":"Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia","volume":"25","author":"Peyvandi","year":"2019","journal-title":"Haemophilia"},{"key":"2025100219514318800_hvaf085-B4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025100219514318800_hvaf085-B5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"8","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2025100219514318800_hvaf085-B6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/hum.2022.169","article-title":"Liver gene therapy","volume":"33","author":"Nathwani","year":"2022","journal-title":"Hum Gene Ther"},{"key":"2025100219514318800_hvaf085-B7","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2025100219514318800_hvaf085-B8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"},{"key":"2025100219514318800_hvaf085-B9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"2025100219514318800_hvaf085-B10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"2025100219514318800_hvaf085-B11","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"2025100219514318800_hvaf085-B12","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"2025100219514318800_hvaf085-B13","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"2025100219514318800_hvaf085-B14","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","article-title":"Valoctocogene roxaparvovec: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"2025100219514318800_hvaf085-B15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","article-title":"Etranacogene dezaparvovec: first approval drugs. 2023","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"2025100219514318800_hvaf085-B16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","article-title":"Fidanacogene elaparvovec: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"2025100219514318800_hvaf085-B17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther"},{"key":"2025100219514318800_hvaf085-B18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100219514318800_hvaf085-B19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol Ther"},{"key":"2025100219514318800_hvaf085-B20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100219514318800_hvaf085-B21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100219514318800_hvaf085-B22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100219514318800_hvaf085-B23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100219514318800_hvaf085-B24","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"key":"2025100219514318800_hvaf085-B25","doi-asserted-by":"crossref","first-page":"10228","DOI":"10.3390\/ijms231810228","article-title":"The arrival of gene therapy for patients with hemophilia A","volume":"23","author":"Castaman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025100219514318800_hvaf085-B26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"The Lancet"},{"key":"2025100219514318800_hvaf085-B27","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1182\/bloodadvances.2024013750","article-title":"Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice","volume":"8","author":"La Mura","year":"2024","journal-title":"Blood Adv"},{"key":"2025100219514318800_hvaf085-B28","doi-asserted-by":"crossref","first-page":"109064","DOI":"10.1016\/j.thromres.2024.109064","article-title":"Liver health in hemophilia in the era of gene therapy","volume":"240","author":"Dargaud","year":"2024","journal-title":"Thromb Res"},{"key":"2025100219514318800_hvaf085-B29","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jtha.2024.08.018","article-title":"The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia","volume":"22","author":"La Mura","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2025100219514318800_hvaf085-B30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: management of alcohol-related liver disease","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2025100219514318800_hvaf085-B31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","article-title":"Occult hepatitis B virus infection","volume":"46","author":"Raimondo","year":"2007","journal-title":"J Hepatol"},{"key":"2025100219514318800_hvaf085-B32","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: autoimmune hepatitis","volume":"63","author":"European Association for the Study of the Liver","year":"2015","journal-title":"J Hepatol"},{"key":"2025100219514318800_hvaf085-B33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.dld.2015.11.013","article-title":"Celiac disease-related hepatic injury: insights into associated conditions and underlying pathomechanisms","volume":"48","author":"Marciano","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2025100219514318800_hvaf085-B34","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.dld.2022.06.023","article-title":"Guidelines of the Italian societies of gastroenterology on the diagnosis and management of coeliac disease and dermatitis herpetiformis","volume":"54","author":"Zingone","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2025100219514318800_hvaf085-B35","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"2025100219514318800_hvaf085-B36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update","volume":"75","author":"European Association for the Study of the Liver","year":"2021","journal-title":"J Hepatol"},{"key":"2025100219514318800_hvaf085-B37","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep4.1794","article-title":"Definition of healthy ranges for alanine aminotransferase levels: a 2021 update","volume":"5","author":"Valenti","year":"2021","journal-title":"Hepatol Commun"},{"key":"2025100219514318800_hvaf085-B38","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2353\/ajpath.2006.051296","article-title":"Systemic viral infections and collateral damage in the liver","volume":"168","author":"Adams","year":"2006","journal-title":"Am J Patho"},{"key":"2025100219514318800_hvaf085-B39","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/clinchem\/21.8.1077","article-title":"Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values","volume":"21","author":"Siest","year":"1975","journal-title":"Clin Chem"},{"key":"2025100219514318800_hvaf085-B40","first-page":"185","article-title":"Long-term variation in plasma activities of aspartate transaminase and alkaline phosphatase in health","volume":"44","author":"Levin","year":"1973","journal-title":"Clin Sci Mol Med"},{"key":"2025100219514318800_hvaf085-B41","doi-asserted-by":"crossref","first-page":"e0422","DOI":"10.1097\/HC9.0000000000000422","article-title":"Alpha-fetoprotein: past, present, and future","volume":"8","author":"Yeo","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025100219514318800_hvaf085-B42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00004836-200012000-00007","article-title":"Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels","volume":"31","author":"Tangkijvanich","year":"2000","journal-title":"J Clin Gastroenterol"},{"key":"2025100219514318800_hvaf085-B43","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1373\/clinchem.2017.284356","article-title":"Advances in the treatment of hemophilia: implications for laboratory testing","volume":"65","author":"Tripodi","year":"2019","journal-title":"Clin Chem"},{"key":"2025100219514318800_hvaf085-B44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1055\/s-0042-1758870","article-title":"Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments","volume":"49","author":"Bowyer","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"2025100219514318800_hvaf085-B45","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1538-7836.2004.00657.x","article-title":"Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr factor VIII:C activity in hemophilic plasma using one-stage clotting assays","volume":"2","author":"Ingerslev","year":"2004","journal-title":"J Thromb Haemost"},{"key":"2025100219514318800_hvaf085-B46","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood"},{"key":"2025100219514318800_hvaf085-B47","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/jth.15281","article-title":"Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua","volume":"19","author":"Robinson","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/71\/10\/1024\/63976382\/hvaf085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/71\/10\/1024\/63976382\/hvaf085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:51:53Z","timestamp":1759449113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/71\/10\/1024\/8225038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,8,7]]},"published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvaf085","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,7]]}}}